Damage control at the DNA level
Invirsa’s lead compound (INV-102), quickly and predictably augments the body’s response to DNA damage, greatly improving cell stability at the critical moment.
Announcement
Invirsa Announces 5 year, $29.6 million partnership with BARDA to develop a treatment for ocular conditions associated with DNA damage, including Sulfur Mustard Gas injury.
Invirsa is on the move. Stay up to date with the latest developments:
Lead Indications
[Parallel Development]
Ocular Injury From Sulphur Mustard Gas
Sulphur mustard gas causes significant, DNA injury to multiple areas of the eye. An untreated injury has a high likelihood of resulting in permanent vision damage. INV-102 helps maintain cellular stability, leading to a more complete DNA repair and significantly better recovery.
Acute Infectious Keratoconjunctivitis
In the US alone, there are approximately 5 million cases of infectious conjunctivitis annually. 80% of those cases are viral, for which there is no approved treatment. This leads to an over prescription of ineffective antibiotics and billions of dollars in lost productivity. INV-102 is expected to a be an effective treatment for both viral and bacterial conjunctivitis.
BARDA funding will support the development of INV-102 for both indications, with the goal of having INV-102 readily available nationwide.
Dive into the science
A unique perspective on drug development
Drawing on a wide breadth of knowledge, Invirsa’s leadership team and scientific advisory board bring a new approach to tackling big market pharmaceuticals.
Meet the teamOur Investors
